Cartesian Therapeutics Inc (RNAC) FinancialsRNACFinancialCartesian Therapeutics Inc

Evaluating the bottom line, Cartesian Therapeutics, Inc. maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -71351.28%, while the net margin is -30016.67%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively RNAC converts its operational activities into shareholder value.

In the context of the broader market, RNAC competes directly with industry leaders such as FATE and IVVD. With a market capitalization of $267.46M, it holds a significant position in the sector. When comparing efficiency, RNAC's gross margin of 100.00% stands against FATE's 100.00% and IVVD's 91.09%. Such benchmarking helps identify whether Cartesian Therapeutics, Inc. is trading at a premium or discount relative to its financial performance.

The company's total revenue for Q1 2025 was $1,100,000, and it has shown a gross margin of 100% across several quarters, indicating strong profitability potential. However, it has faced significant net income losses, with a net income of -$39,182,000 in Q1 2026.